AU2023202736B2 — Assays for diagnosing and evaluating treatment options for fabry disease
Assigned to Amicus Therapeutics Inc · Expires 2025-05-29 · 1y expired
What this patent protects
Provided is a method for the treatment of Fabry disease in a human patient with a specific a-galactosidase A mutation comprising administering to the patient an effective amount of 1-deoxygalactonojirimycin or a salt thereof.
USPTO Abstract
Provided is a method for the treatment of Fabry disease in a human patient with a specific a-galactosidase A mutation comprising administering to the patient an effective amount of 1-deoxygalactonojirimycin or a salt thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.